Cargando…

Novel Rivastigmine Derivatives as Promising Multi-Target Compounds for Potential Treatment of Alzheimer’s Disease

Alzheimer’s disease (AD) is the most serious and prevalent neurodegenerative disorder still without cure. Since its aetiology is diverse, recent research on anti-AD drugs has been focused on multi-target compounds. In this work, seven novel hybrids (RIV–BIM) conjugating the active moiety of the drug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vicente-Zurdo, David, Rosales-Conrado, Noelia, León-González, M. Eugenia, Brunetti, Leonardo, Piemontese, Luca, Pereira-Santos, A. Raquel, Cardoso, Sandra M., Madrid, Yolanda, Chaves, Sílvia, Santos, M. Amélia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313321/ https://www.ncbi.nlm.nih.gov/pubmed/35884815 http://dx.doi.org/10.3390/biomedicines10071510

Ejemplares similares

Rivastigmine–Benzimidazole Hybrids as Promising Multitarget Metal-Modulating Compounds for Potential Treatment of Neurodegenerative Diseases
por: Vicente-Zurdo, David, et al.
Publicado: (2023)

A combined analytical-chemometric approach for the in vitro determination of polyphenol bioaccessibility by simulated gastrointestinal digestion
por: Gómez-Mejía, Esther, et al.
Publicado: (2022)

Effect of Storage and Drying Treatments on Antioxidant Activity and Phenolic Composition of Lemon and Clementine Peel Extracts
por: Gómez-Mejía, Esther, et al.
Publicado: (2023)

Valorization of Citrus reticulata Blanco Peels to Produce Enriched Wheat Bread: Phenolic Bioaccessibility and Antioxidant Potential
por: Gómez-Mejía, Esther, et al.
Publicado: (2023)

Derivatives of Tenuazonic Acid as Potential New Multi-Target Anti-Alzheimer’s Disease Agents
por: Poliseno, Viviana, et al.
Publicado: (2021)

Influence of Rivastigmine transdermal on butyrylcholinesterase levels in patients with Alzheimer's disease
por: dos Santos, Gustavo Alves Andrade, et al.
Publicado: (2011)

Rivastigmine in the treatment of Alzheimer’s disease: an update
por: Onor, Maria Luisa, et al.
Publicado: (2007)

Rivastigmine in the treatment of patients with Alzheimer’s disease
por: Müller, Thomas
Publicado: (2007)

Donepezil structure-based hybrids as potential multifunctional anti-Alzheimer’s drug candidates
por: Piemontese, Luca, et al.
Publicado: (2018)

Rivastigmine in Alzheimer’s disease: Cognitive function and quality of life
por: Annicchiarico, Roberta, et al.
Publicado: (2007)

Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
por: Wentrup, Andreas, et al.
Publicado: (2009)

Design, Synthesis, and In Vitro Evaluation of Hydroxybenzimidazole-Donepezil Analogues as Multitarget-Directed Ligands for the Treatment of Alzheimer’s Disease
por: Chaves, Sílvia, et al.
Publicado: (2020)

Novel Donepezil–Arylsulfonamide Hybrids as Multitarget-Directed Ligands for Potential Treatment of Alzheimer’s Disease
por: Queda, Fausto, et al.
Publicado: (2021)

Deep Eutectic Solvents as Effective Reaction Media for the Synthesis of 2-Hydroxyphenylbenzimidazole-Based Scaffolds en Route to Donepezil-Like Compounds
por: Piemontese, Luca, et al.
Publicado: (2020)

Novel tacrine–benzofuran hybrids as potential multi-target drug candidates for the treatment of Alzheimer’s Disease
por: Fancellu, Gaia, et al.
Publicado: (2019)

Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study
por: Tsuno, Norifumi, et al.
Publicado: (2019)

Esophagectasis Related to Rivastigmine
por: Sasaki, Osamu, et al.
Publicado: (2019)

Pharmacogenetic Study on the Effect of Rivastigmine on PS2 and APOE Genes in Iranian Alzheimer Patients
por: Zamani, M., et al.
Publicado: (2011)

The Effect of Vascular Risk Factors on the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer's Disease
por: Farlow, M.R., et al.
Publicado: (2011)

Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice
por: Seibert, Johannes, et al.
Publicado: (2012)

Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
por: Ray, Balmiki, et al.
Publicado: (2020)

Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease
por: Shimura, Hideki, et al.
Publicado: (2021)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
por: Siddique, Yasir Hasan, et al.
Publicado: (2022)

Neuroprotective Action of Multitarget 7-Aminophenanthridin-6(5H)-one Derivatives against Metal-Induced Cell Death and Oxidative Stress in SN56 Cells
por: Moyano, Paula, et al.
Publicado: (2021)

Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review
por: Kurz, A, et al.
Publicado: (2009)

Mitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice
por: Kondak, Constantin, et al.
Publicado: (2023)

Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer’s disease
por: Ismail, Manal Fouad, et al.
Publicado: (2013)

Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer’s disease
por: Kano, Osamu, et al.
Publicado: (2013)

The Effect of Rivastigmine Transdermal Patch on Sleep Apnea in Patients with Probable Alzheimer's Disease
por: Kim, Hyeyun, et al.
Publicado: (2016)

Correction: Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
por: Ray, Balmiki, et al.
Publicado: (2020)

Novel Phenothiazine/Donepezil-like Hybrids Endowed with Antioxidant Activity for a Multi-Target Approach to the Therapy of Alzheimer’s Disease
por: Carocci, Alessia, et al.
Publicado: (2022)

Treatment of pediatric antimuscarinic delirium with oral rivastigmine
por: Yakey, Brandtly, et al.
Publicado: (2023)

An Atypical Cutaneous Reaction to Rivastigmine Transdermal Patch
por: Grieco, T., et al.
Publicado: (2011)

Rivastigmine in moderately severe-to-severe Alzheimer’s disease: Severe Impairment Battery factor analysis
por: Ferris, Steven, et al.
Publicado: (2013)

Effects of Rivastigmine on Brain Functional Networks in Patients With Alzheimer Disease Based on the Graph Theory
por: Zhang, Jiangtao, et al.
Publicado: (2021)

Zinc Chloride-Catalyzed Synthesis of Carbamates: An Application for the Synthesis of the Anti-Alzheimer’s Drug Rivastigmine
por: Gayke, Manoj, et al.
Publicado: (2022)

Acquired Localized Hypertrichosis Induced by Rivastigmine
por: Imbernón-Moya, Adrian, et al.
Publicado: (2016)

EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease*
por: Gauthier, S, et al.
Publicado: (2007)

Characteristics of patients with Alzheimer’s disease who switch to rivastigmine transdermal patches in routine clinical practice
por: López-Pousa, Secundino, et al.
Publicado: (2013)

Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease
por: Moretti, Davide V., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ec7r1esv5c9jndcv2vm38v11og